Drug development
Non-clinical studies required for new drug development – Part I: early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies
... The drug design process occurs frequently, but not necessarily, by means of computational modeling approaches that are able to selectively interact with the identified ...rational drug design and accelerate ...
9
<it>ADDME – Avoiding Drug Development Mistakes Early</it>: central nervous system drug discovery perspective
... The focus of this session is the transition from lead compound to clinical testing, the scenic stretch of drug development often referred to as the “Valley of Death”. Several factors converge to kill ...
4
Leishmania proteases: new targets for rational drug development.
... Leishmania PROTEASES: NEW TARGETS FOR RATIONAL DRUG DEVELOPMENT. Leishmania causes tegumental and visceral diseases called leishmaniasis. Disease control is possible interrupting the transmission cycle, but ...
8
a and b-glucosidases as molecular targets for drug development.
... α AND β-GLUCOSIDASES AS MOLECULAR TARGETS FOR DRUG DEVELOPMENT. Glucosidases are involved in key steps in the processing of oligosaccharides by cleaving O-glucose residues. Since they catalyze breaking and ...
4
Advances and challenges in therapeutic monoclonal antibodies drug development
... Antibody engineering technologies allowed the development of mAbs with binding, functional and pharmacological characteristics suitable for its therapeutic use. Initially the focus of antibody engineering was the ...
15
Natural products as new antimitotic compounds for anticancer drug development
... the development and progression of many human cancers, suggesting that this class of proteins is an interesting target for new anti- cancer therapy strategies ...
11
Potential drug development candidates for human soil-transmitted helminthiases.
... the drug against specific soil-transmitted helminths (For detailed information see Appendix ...the drug has a broad spectrum of activity [38,41] and might have lower production ...
8
Ergosterol biosynthesis and drug development for Chagas disease
... ed development was the surprising discovery that amio- darone, a bis-aryl-ketone ...antiarrhythmic drug in chronic Chagas disease patients with cardiac compromise (Rosenbaum et ...this drug with ...
8
Applications of combinatorial Chemistry to drug development.
... As coleções combinatórias podem ainda ser divididas entre aquelas preparadas em solução, assim como na síntese orgânica clássica; e aquelas onde a síntese dos componentes é realizada em [r] ...
7
Sofia Leite PhD thesis
... In this work, a perfused bioreactor system for long term maintenance of primary cultures of human hepatocyte spheroids was established and tested. In this system, hepatocyte spheroids reproducibly recapitulated in vivo ...
211
Development of new antiepileptic drug candidates: a set of lamotrigine-related compounds
... preclinical drug development (Löscher and Schmidt, ...the development of similar reliable models in mice has proven difficult, mainly as a result of genetic interstrain and intrastrain differences in ...
322
Bioethical issues in the development of biopharmaceuticals
... Abstract: Development of biopharmaceuticals is a challenging issue in ...biopharmaceutical drug development, ...biopharmaceutical drug development are their cost/effectiveness ratio, ...
8
Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials.
... Consequently, in most of the HIV clinical trial using the TLOVR algorithm one observed at least 5–10% of ‘non-virologic’ failures. HIV noninferiority trial has emerged as the new standard design for HIV drug ...
8
Development of and access to products for neglected diseases.
... diseases and tuberculosis included in Trouiller et al. Large new cooperative ventures have begun to take shape, including the Global Network for Neglected Tropical Disease Control, Medi- cines for Malaria Venture (MMV), ...
5
In vitro and in vivo experimental models for drug screening and development for Chagas disease
... All proposed steps were discussed separately, taking into account the well-accepted current requirements for the development of novel anti-T. cruzi compounds (Ur- bina 1999, Nwaka & Hudson 2006), which ...
6
Characteristics, complexation and analytical methods of darunavir
... Most newly-discovered chemical entities, despite the high therapeutic activity, have low water solubility and poor bioavailability, leading to poor absorption in the gastro intestinal tract [7]. The important ...
11
Development of a new immunoliposome drug delivery system for treatment of pneumococcal meningitis
... the development of novel drug delivery systems that can cross the BBB and release the therapeutic molecule into the brain are urgently ...the development of an immunoliposome as a drug ...
70
Rev. Bras. Cienc. Farm. vol.44 número1
... Our study found that NSAIDs and antibiotics were the most-prescribed drugs. This is in accordance with the fact that the respiratory system diseases (ICD: J00-J99), particularly the acute upper and lower respiratory ...
11
Braz. J. Pharm. Sci. vol.49 número3
... the development of a solid dosage form, because commercial production requires a continuous low of powder mixes during the manufacturing process (Yang, Venkateshi, Fassihi, ...
8
Development of a new drug delivery system for future application in cancer therapy
... Tumor development is associated with different cellular stresses promoted by the surrounding environment (radiation and chemicals), lifestyle behaviors (diet and smoking), or by inherited predispositions ...
89